KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Retained Earnings (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Retained Earnings for 17 consecutive years, with $49.8 billion as the latest value for Q4 2025.

  • Quarterly Retained Earnings rose 5.33% to $49.8 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $49.8 billion through Dec 2025, up 5.33% year-over-year, with the annual reading at $49.8 billion for FY2025, 5.33% up from the prior year.
  • Retained Earnings hit $49.8 billion in Q4 2025 for Abbott Laboratories, up from $49.1 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $49.8 billion in Q4 2025 to a low of -$9.3 billion in Q1 2021.
  • Historically, Retained Earnings has averaged $17.9 billion across 5 years, with a median of $31.2 billion in 2021.
  • Biggest five-year swings in Retained Earnings: tumbled 129.97% in 2022 and later skyrocketed 702.9% in 2024.
  • Year by year, Retained Earnings stood at -$8.4 billion in 2021, then grew by 3.86% to -$8.1 billion in 2022, then rose by 2.63% to -$7.8 billion in 2023, then skyrocketed by 702.9% to $47.3 billion in 2024, then rose by 5.33% to $49.8 billion in 2025.
  • Business Quant data shows Retained Earnings for ABT at $49.8 billion in Q4 2025, $49.1 billion in Q3 2025, and -$6.6 billion in Q2 2025.